Drug intelligence / Profile preview

EX-054

Development stage: Preclinical
Lead developer: Excelsior
Modality: Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies

Overview

EX-054 is an investigational gene therapy candidate currently in the preclinical stage of development by Excelsior (Excelsior Group). The program is managed by the company's Asia-Pacific Special Disease Research Center. While the specific genetic target and the exact nature of the "Asia-Pacific Special Disease" (亞太特殊疾病) have not been publicly disclosed, the program focuses on utilizing gene therapy modalities to address regional health needs in the Asia-Pacific area.

Other names: EX-054 gene therapyEX054 gene therapyEX 054 gene therapy

Beyond the preview

Go deeper on EX-054.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EX-054.

Explore the full profile